RET kinase inhibitors like pralsetinib and selpercatinib increase hypertension by upregulation of CD47 (integrin-associated protein), downregulation of cyclic guanosine monophosphate (cGMP), and reduction of nitric oxide (NO) [48]. The gene discussed is CD47; the disease is hypertensive disorder.